STOCK TITAN

[SCHEDULE 13G] Tharimmune, Inc. Passive Investment Disclosure (>5%)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Tharimmune, Inc. (THAR) received a Schedule 13G reporting significant share ownership by LCV-affiliated investment entities and individuals. The reporting group discloses beneficial ownership of up to 9.99% of Tharimmune’s common stock for each reporting person, based on 36,444,785 shares outstanding as stated in a December 24, 2025 proxy statement.

The group collectively holds 16,500,504 warrants exercisable into 16,500,504 shares of common stock at an exercise price of $0.0001 per share. These warrants are subject to a 9.99% beneficial ownership blocker, which prevents any holder from exercising warrants to the extent it would push their ownership above 9.99% of the company’s outstanding shares after exercise. The filers certify that the securities were not acquired to change or influence control of Tharimmune.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: As of the date hereof, the Reporting Person's beneficial ownership consists of: (i) 757,724 shares of Common Stock, and (ii) 3,207,035 shares of Common Stock issuable upon the exercise of warrants (the "Warrants") within the next sixty (60) days. The aggregate amount beneficially owned does not consist of 920,917 shares of Common Stock, issuable upon the exercise of the Warrants because the Warrants are subject to restrictions included in the Subscription Agreement between the Issuer and the Reporting Person, which include a 9.99% blocker. The percentage reported in Item 11 is based on 36,444,785 shares of common stock outstanding as reported in the Issuer's definitive proxy statement on Schedule 14A filed with the SEC on December 24, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: As of the date hereof, the Reporting Person's beneficial ownership consists of: (i) 757,724 shares of Common Stock, and (ii) 3,207,035 shares of Common Stock issuable upon the exercise of the Warrant within the next sixty (60) days. Does not consist of 920,917 shares of Common Stock, issuable upon the exercise of the Warrants because the Warrants are subject to restrictions included in the Subscription Agreement between the Issuer and the Reporting Person, which include a 9.99% blocker. The percentage reported in Item 11 is based on 36,444,785 shares of common stock outstanding as reported in the Issuer's definitive proxy statement on Schedule 14A filed with the SEC on December 24, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: As of the date hereof, the Reporting Person's beneficial ownership consists of: (i) 757,724 shares of Common Stock, and (ii) 3,207,035 shares of Common Stock issuable upon the exercise of the Warrant within the next sixty (60) days. Does not consist of (i) 920,917 shares of Common Stock, issuable upon the exercise of the Warrants because the Warrants are subject to restrictions included in the Subscription Agreement between the Issuer and the Reporting Person, which include a 9.99% blocker. The percentage reported in Item 11 is based on 36,444,785 shares of common stock outstanding as reported in the Issuer's definitive proxy statement on Schedule 14A filed with the SEC on December 24, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: As of the date hereof, the Reporting Person's beneficial ownership consists of 4,044,927 shares of Common Stock issuable upon the exercise of the Warrants within the next sixty (60) days. Does not consist of 8,282,625 shares of Common Stock, issuable upon the exercise of the Warrants because the Warrants are subject to restrictions included in the Subscription Agreement between the Issuer and the Reporting Person, which include a 9.99% blocker. The percentage reported in Item 11 is based on 36,444,785 shares of common stock outstanding as reported in the Issuer's definitive proxy statement on Schedule 14A filed with the SEC on December 24, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: As of the date hereof, the Reporting Person's beneficial ownership consists of 4,044,927 shares of Common Stock issuable upon the exercise of the Warrants within the next sixty (60) days. Does not consist of 8,282,625 shares of Common Stock, issuable upon the exercise of the Warrants because the Warrants are subject to restrictions included in the Subscription Agreement between the Issuer and the Reporting Person, which include a 9.99% blocker. The percentage reported in Item 11 is based on 36,444,785 shares of common stock outstanding as reported in the Issuer's definitive proxy statement on Schedule 14A filed with the SEC on December 24, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: As of the date hereof, the Reporting Person's beneficial ownership consists of: (i) 757,724 shares of Common Stock, and (ii) 3,199,362 shares of Common Stock issuable upon the exercise of the Warrant within the next sixty (60) days. Does not consist of 13,301,142 shares of Common Stock, issuable upon the exercise of the Warrants because the Warrants are subject to restrictions included in the Subscription Agreement between the Issuer and the Reporting Person, which include a 9.99% blocker. The percentage reported in Item 11 is based on 36,444,785 shares of common stock outstanding as reported in the Issuer's definitive proxy statement on Schedule 14A filed with the SEC on December 24, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: As of the date hereof, the Reporting Person's beneficial ownership consists of: (i) 757,724 shares of Common Stock, and (ii) 3,199,362 shares of Common Stock issuable upon the exercise of the Warrant within the next sixty (60) days. Does not consist of 13,301,142 shares of Common Stock, issuable upon the exercise of the Warrants because the Warrants are subject to restrictions included in the Subscription Agreement between the Issuer and the Reporting Person, which include a 9.99% blocker. The percentage reported in Item 11 is based on 36,444,785 shares of common stock outstanding as reported in the Issuer's definitive proxy statement on Schedule 14A filed with the SEC on December 24, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: As of the date hereof, the Reporting Person's beneficial ownership consists of: (i) 757,724 shares of Common Stock, and (ii) 3,199,362 shares of Common Stock issuable upon the exercise of the Warrant within the next sixty (60) days. Does not consist of 13,301,142 shares of Common Stock, issuable upon the exercise of the Warrants because the Warrants are subject to restrictions included in the Subscription Agreement between the Issuer and the Reporting Person, which include a 9.99% blocker. The percentage reported in Item 11 is based on 36,444,785 shares of common stock outstanding as reported in the Issuer's definitive proxy statement on Schedule 14A filed with the SEC on December 24, 2025.


SCHEDULE 13G



LCV Fund III, L.P.
Signature:/s/ Brian Whitehurst
Name/Title:by LCV Fund III GP, L.P., its general partner, by LCV GP III, L.L.C., its general partner, Brian Whitehurst, Chief of Staff
Date:02/02/2026
LCV Fund III GP, L.P.
Signature:/s/ Brian Whitehurst
Name/Title:by LCV GP III, L.L.C., its general partner, Brian Whitehurst, Chief of Staff
Date:02/02/2026
LCV GP III, L.L.C.
Signature:/s/ Brian Whitehurst
Name/Title:Brian Whitehurst, Chief of Staff
Date:02/02/2026
LCV Fund VIII, L.P.
Signature:/s/ Brian Whitehurst
Name/Title:by LCV GP VIII, L.L.C., its general partner, Brian Whitehurst, Chief of Staff
Date:02/02/2026
LCV GP VIII, L.L.C.
Signature:/s/ Brian Whitehurst
Name/Title:Brian Whitehurst, Chief of Staff
Date:02/02/2026
LCV Blockchain Management, LLC
Signature:/s/ Brian Whitehurst
Name/Title:Brian Whitehurst, Chief of Staff
Date:02/02/2026
Murtaza S. Akbar
Signature:/s/ Murtaza S. Akbar
Name/Title:Murtaza S. Akbar
Date:02/02/2026
Emil Woods
Signature:/s/ Emil Woods
Name/Title:Emil Woods
Date:02/02/2026
Tharimmune Inc

NASDAQ:THAR

THAR Rankings

THAR Latest News

THAR Latest SEC Filings

THAR Stock Data

155.35M
53.96M
17.13%
1.5%
12.08%
Biotechnology
Pharmaceutical Preparations
Link
United States
BRIDGEWATER